- Home
- CCCC vs SOPH Comparison
CCCC vs SOPH Comparison
Compare CCCC & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- SOPH
- Stock Information
- Founded
- CCCC 2015
- SOPH 2011
- Country
- CCCC United States
- SOPH Switzerland
- Employees
- CCCC N/A
- SOPH N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCCC Health Care
- SOPH Health Care
- Exchange
- CCCC Nasdaq
- SOPH Nasdaq
- Market Cap
- CCCC 242.3M
- SOPH 231.8M
- IPO Year
- CCCC 2020
- SOPH 2021
- Fundamental
- Price
- CCCC $2.44
- SOPH $4.64
- Analyst Decision
- CCCC Strong Buy
- SOPH Strong Buy
- Analyst Count
- CCCC 4
- SOPH 1
- Target Price
- CCCC $8.50
- SOPH $7.00
- AVG Volume (30 Days)
- CCCC 1.5M
- SOPH 131.6K
- Earning Date
- CCCC 11-06-2025
- SOPH 11-04-2025
- Dividend Yield
- CCCC N/A
- SOPH N/A
- EPS Growth
- CCCC N/A
- SOPH N/A
- EPS
- CCCC N/A
- SOPH N/A
- Revenue
- CCCC $30,108,000.00
- SOPH $73,297,000.00
- Revenue This Year
- CCCC N/A
- SOPH $16.60
- Revenue Next Year
- CCCC N/A
- SOPH $19.09
- P/E Ratio
- CCCC N/A
- SOPH N/A
- Revenue Growth
- CCCC N/A
- SOPH 13.66
- 52 Week Low
- CCCC $1.09
- SOPH $2.58
- 52 Week High
- CCCC $5.10
- SOPH $5.30
- Technical
- Relative Strength Index (RSI)
- CCCC 49.92
- SOPH 56.01
- Support Level
- CCCC $2.39
- SOPH $3.83
- Resistance Level
- CCCC $2.63
- SOPH $4.70
- Average True Range (ATR)
- CCCC 0.16
- SOPH 0.33
- MACD
- CCCC -0.00
- SOPH -0.05
- Stochastic Oscillator
- CCCC 57.63
- SOPH 62.50
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.